Androgens, diabetes and prostate cancer

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages

  Grossmann, Mathis ^a   Wittert, Gary ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANDROGEN; ANDROSTANOLONE; C PEPTIDE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FINASTERIDE; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; GONADORELIN AGONIST; GOSERELIN; HOMEOBOX TRANSCRIPTION FACTOR 13; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; BIOSYNTHESIS; BODY COMPOSITION; BODY MASS; CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURFACE; DIABETES MELLITUS; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; ETHNICITY; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID DIET; LIPOGENESIS; LONG TERM CARE; LOW FAT DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT; OBESITY; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PREVALENCE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT GAIN; WEIGHT REDUCTION;

ANDROGENS; ANIMALS; DIABETES MELLITUS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84867427177     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0067     Document Type: Review

References (101)

1. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K & Virtamo J 2009 Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. Journal of the National Cancer Institute 101 1272-1279. (doi:10.1093/jnci/djp260)
2. Ammirante M, Luo JL, Grivennikov S, Nedospasov S & Karin M 2010 B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464 302-305. (doi:10.1038/nature08782)
3. Araujo AB & Wittert GA 2011 Endocrinology of the aging male. Best Practice & Research. Clinical Endocrinology & Metabolism 25 303-319. (doi:10.1016/j.beem.2010.11. 004)
4. Astorg P 2004 Dietary n-6 and n-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes & Control 15 367-386. (doi:10.1023/B:CACO.0000027498. 94238.a3)
5. Atlantis E, Martin SA, Haren MT, O'Loughlin PD, Taylor AW, Anand-Ivell R, Ivell R & Wittert GA 2009 Demographic, physical and lifestyle factors associated with androgen status: the Florey Adelaide Male Ageing Study (FAMAS). Clinical Endocrinology 71 261-272. (doi:10.1111/j.1365- 2265.2008.03463.x)
6. Atlantis E, Lange K, Martin S, Haren MT, Taylor A, O'Loughlin PD, Marshall V & Wittert GA 2011 Testosterone and modifiable risk factors associated with diabetes in men. Maturitas 68 279-285. (doi:10.1016/ j.maturitas.2010.12.007)
7. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS & Montori VM 2010 Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 95 2536-2559. (doi:10.1210/jc.2009-2354)
8. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T & Cao Y 2004 Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. PNAS 101 2476-2481. (doi:10.1073/ pnas.0308671100)
9. Bub JD, Miyazaki T & Iwamoto Y 2006 Adiponectin as a growth inhibitor in prostate cancer cells. Biochemical and Biophysical Research Communications 340 1158-1166. (doi:10.1016/j.bbrc.2005.12.103)
10. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL & Bhasin S 2005 Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 60 1451-1457. (doi:10.1093/gerona/60.11.1451)
11. Cavazos DA, Price RS, Apte SS & deGraffenried LA 2011 Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-kappaB. Prostate 71 1420-1428. (doi:10.1002/pros.21359)
12. Chan JM, Gann PH & Giovannucci EL 2005 Role of diet in prostate cancer development and progression. Journal of Clinical Oncology 23 8152-8160. (doi:10.1200/JCO. 2005.03.1492)
13. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E & Parsons JK 2011 The correlation between metabolic syndrome and prostatic diseases. European Urology 61 560-570. (doi:10.1016/j.eururo.2011.11.013)
14. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N et al. 2011 Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 20 2618-2627. (doi:10.1158/1055-9965.EPI-11-0434)
15. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A & Dandona P 2004 Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89 5462-5468. (doi:10.1210/jc.2004-0804)
16. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J & Conti C 2000 Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. PNAS 97 3455-3460. (doi:10.1073/pnas.97.7.3455)
17. Ding EL, Song Y, Malik VS & Liu S 2006 Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. Journal of the American Medical Association 295 1288-1299. (doi:10.1001/jama. 295.11.1288)
18. Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, Thorlacius S, Amundadottir L, Gronberg H, Xu J et al. 2010 Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS ONE 5 e10858. (doi:10.1371/journal.pone.0010858)
19. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y et al. 2012 Germline mutations in HOXB13 and prostatecancer risk. New England Journal of Medicine 366 141-149. (doi:10.1056/NEJMoa1110000)
20. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT et al. 2010 Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism 95 2560-2575. (doi:10.1210/jc.2009-2575)
21. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA & Willett WC 1998 Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes & Control 9 3-9. (doi:10.1023/A:1008822917449)
22. Goldenberg SL, Koupparis A & Robinson ME 2011 Differing levels of testosterone and the prostate: a physiological interplay. Nature Reviews. Urology 8 365-377. (doi:10.1038/nrurol.2011.79)
23. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM et al. 2006 Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiology, Biomarkers & Prevention 15 1977-1983. (doi:10.1158/1055-9965. EPI-06-0477)
24. Gorbachinsky I, Akpinar H & Assimos DG 2010 Metabolic syndrome and urologic diseases. Reviews in Urology 12 e157-e180.
25. Grossmann M 2011 Low testosterone in men with type 2 diabetes: significance and treatment. Journal of Clinical Endocrinology and Metabolism 96 2341-2353. (doi:10.1210/jc.2011-0118)
26. Grossmann M & Zajac JD 2011a Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clinical Endocrinology 74 289-293. (doi:10.1111/j.1365-2265.2010.03939.x)
27. Grossmann M & Zajac JD 2011b Management of side effects of androgen deprivation therapy. Endocrinology and Metabolism Clinics of North America 40 655-671, x. (doi:10.1016/j.ecl.2011.05.004)
28. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD & Jerums G 2008 Low testosterone levels are common and associated with insulin resistance in men with diabetes. Journal of Clinical Endocrinology and Metabolism 93 1834-1840. (doi:10.1210/jc.2007-2177)
29. Grossmann M, Gianatti EJ & Zajac JD 2010 Testosterone and type 2 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 17 247-256. (doi:10.1097/MED. 0b013e32833919cf)
30. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL & Zajac JD 2011 Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Medical Journal of Australia 194 301-306.
31. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L & Zethelius B 2010 The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiology, Biomarkers & Prevention 19 2088-2096. (doi:10.1158/1055-9965.EPI-10-0112)
32. Gu M, Dong X, Zhang X & Niu W 2011 The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis. Molecular Biology Reports 39 2615-2624. (doi:10.1007/s11033-011-1014-9)
33. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A et al. 2007 Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nature Genetics 39 977-983. (doi:10.1038/ng2062)
34. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD & Grossmann M 2011 Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clinical Endocrinology 74 377-383. (doi:10.1111/j.1365-2265.2010.03942.x)
35. Heinze VM & Actis AB 2012 Dietary conjugated linoleic acid and long-chain n-3 fatty acids in mammary and prostate cancer protection: a review. International Journal of Food Sciences and Nutrition 63 66-78. (doi:10.3109/09637486.2011.598849)
36. Ho SM, Lee MT, Lam HM & Leung YK 2011 Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinology and Metabolism Clinics of North America 40 591-614, ix. (doi:10.1016/j.ecl.2011. 05.002)
37. Hsing AW, Sakoda LC & Chua S Jr 2007 Obesity, metabolic syndrome, and prostate cancer. American Journal of Clinical Nutrition 86 s843-s857.
38. Huggins C & Hodges CV 1941 Studies on prostatic cancer: I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
39. Idan A, Griffiths KA, Harwood DT, Seibel MJ, Turner L, Conway AJ & Handelsman DJ 2010 Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Annals of Internal Medicine 153 621-632.
40. Imperato-McGinley J, Guerrero L, Gautier T & Peterson RE 1974 Steroid 5a-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186 1213-1215. (doi:10.1126/science.186.4170. 1213)
41. Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60 277-300. (doi:10.3322/caac.20073)
42. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA et al. 2008 The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Research 68 6762-6769. (doi:10.1158/ 0008-5472.CAN-08-0107)
43. Kapoor D, Aldred H, Clark S, Channer KS & Jones TH 2007 Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30 911-917. (doi:10.2337/dc06-1426)
44. Kasper JS & Giovannucci E 2006 A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 15 2056-2062. (doi:10.1158/1055-9965.EPI-06-0410)
45. Kasper JS, Liu Y & Giovannucci E 2009 Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. International Journal of Cancer 124 1398-1403. (doi:10.1002/ijc.24044)
46. Khoo J, Piantadosi C, Worthley S & Wittert GA 2010 Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. International Journal of Obesity 34 1396-1403. (doi:10.1038/ijo.2010.76)
47. Kim ST, Cheng Y, Hsu FC, Jin T, Kader AK, Zheng SL, Isaacs WB, Xu J & Sun J 2010 Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate 70 1729-1738. (doi:10.1002/pros.21189)
48. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J et al. 2006 Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clinical Cancer Research 12 4662-4670. (doi:10.1158/1078-0432.CCR-06-0459)
49. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H et al. 2011 Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics 43 785-791. (doi:10.1038/ ng.882)
50. Landau D, Tsakok T, Aylwin S & Hughes S 2012 Should testosterone replacement be offered to hypogonadal men treated previously for prostatic carcinoma? Clinical Endocrinology 76 179-181. (doi:10.1111/j.1365-2265. 2011.04233.x)
51. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T & Ma J 2010 A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clinical Chemistry 56 34-43. (doi:10.1373/ clinchem.2009.133272)
52. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A & Hemminki K 2000 Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. New England Journal of Medicine 343 78-85. (doi:10.1056/ NEJM200007133430201)
53. Liverman CT & Blazer DG, eds 2004 In Testosterone and aging: clinical research directives . Washington, DC, USA: The National Academy Press.
54. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, Lubik A, Margiotti K, Fazli L, Adomat H, Wasan KM et al. 2010 Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 70 239-251. (doi:10.1002/ pros.21057)
55. Lu S & Archer MC 2010 Sp1 coordinately regulates de novo lipogenesis and proliferation in cancer cells. International Journal of Cancer 126 416-425. (doi:10.1002/ijc.24761)
56. Lu Y, Zhang Z, Yu H, Zheng SL, Isaacs WB, Xu J & Sun J 2011 Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate 71 955-963. (doi:10.1002/pros.21311)
57. Lund Haheim L, Wisloff TF, Holme I & Nafstad P 2006 Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. American Journal of Epidemiology 164 769-774. (doi:10.1093/aje/kwj284)
58. Ly LP, Sartorius G, Hull L, Leung A, Swerdloff RS, Wang C & Handelsman DJ 2010 Accuracy of calculated free testosterone formulae in men. Clinical Endocrinology 73 382-388. (doi:10.1111/j.1365-2265.2010.03804.x)
59. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M & Stampfer MJ 2008 Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncology 9 1039-1047. (doi:10.1016/S1470-2045(08)70235-3)
60. MacInnis RJ & English DR 2006 Body size and composition and prostate cancer risk: systematic review and metaregression analysis. Cancer Causes & Control 17 989-1003. (doi:10.1007/s10552-006-0049-z)
61. Mah PM & Wittert GA 2010 Obesity and testicular function. Molecular and Cellular Endocrinology 316 180-186. (doi:10.1016/j.mce.2009.06.007)
62. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG et al. 2006 Effect of testosterone replacement therapy on prostate tissue in men with lateonset hypogonadism: a randomized controlled trial. Journal of the American Medical Association 296 2351-2361. (doi:10.1001/jama.296.19.2351)
63. Marks LS, Mostaghel EA & Nelson PS 2008 Prostate tissue androgens: history and current clinical relevance. Urology 72 247-254. (doi:10.1016/j. urology.2008.03.033)
64. Martin RM, Vatten L, Gunnell D, Romundstad P & Nilsen TI 2009 Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes & Control 20 1181-1192. (doi:10.1007/s10552- 009-9319-x)
65. McEntee MF, Ziegler C, Reel D, Tomer K, Shoieb A, Ray M, Li X, Neilsen N, Lih FB, O'Rourke D et al. 2008 Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. American Journal of Pathology 173 229-241. (doi:10.2353/ajpath. 2008.070989)
66. Meyer TE, Boerwinkle E, Morrison AC, Volcik KA, Sanderson M, Coker AL, Pankow JS & Folsom AR 2010 Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiology, Biomarkers & Prevention 19 558-565. (doi:10.1158/ 1055-9965.EPI-09-0902)
67. Misra UK, Kaczowka S & Pizzo SV 2010 Inhibition of NF-kappaB1 and NF-kappaB2 activation in prostate cancer cells treated with antibody against the carboxyl terminal domain of GRP78: effect of p53 upregulation. Biochemical and Biophysical Research Communications 392 538-542. (doi:10.1016/j.bbrc.2010.01. 058)
68. Morgentaler A 2011 Testosterone and prostate cancer: what are the risks for middle-aged men? Urologic Clinics of North America 38 119-124. (doi:10.1016/j.ucl.2011. 02.002)
69. Morgentaler A & Traish AM 2009 Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. European Urology 55 310-320. (doi:10.1016/j.eururo. 2008.09.024)
70. Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL & Pollak M 2010 Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prevention Research 3 279-289. (doi:10.1158/1940-6207.CAPR- 09-0188)
71. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA & Choueiri TK 2011 Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Journal of the American Medical Association 306 2359-2366. (doi:10.1001/ jama.2011.1745)
72. Onuma M, Bub JD, Rummel TL & Iwamoto Y 2003 Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. Journal of Biological Chemistry 278 42660-42667. (doi:10.1074/jbc. M304984200)
73. Page ST, Lin DW, Mostaghel EA, Marck BT, Wright JL, Wu J, Amory JK, Nelson PS & Matsumoto AM 2011 Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomizedcontrolled trial. Journal of Clinical Endocrinology and Metabolism 96 430-437. (doi:10.1210/jc.2010-1865)
74. Risbridger GP, Davis ID, Birrell SN & Tilley WD 2010 Breast and prostate cancer: more similar than different. Nature Reviews. Cancer 10 205-212. (doi:10.1038/ nrc2795)
75. Roddam AW, Allen NE, Appleby P & Key TJ 2008a Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 100 170-183. (doi:10.1093/jnci/djm323)
76. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A et al. 2008b Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Annals of Internal Medicine 149 461-471. W483-468.
77. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ & Calle EE 2005 Diabetes and risk of prostate cancer in a prospective cohort of US men. American Journal of Epidemiology 161 147-152. (doi:10.1093/aje/kwh334)
78. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ & Calle EE 2007 Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology, Biomarkers & Prevention 16 63-69. (doi:10.1158/1055-9965.EPI-06-0754)
79. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM & Martin RM 2009 Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. International Journal of Cancer 124 2416-2429. (doi:10.1002/ijc.24202)
80. Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, Colombo R, Freschi M, Rigatti P & Montorsi F 2011 Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer 117 3953-3962. (doi:10.1002/cncr.25985)
81. Satariano WA, Ragland KE & Van Den Eeden SK 1998 Cause of death inmen diagnosed with prostate carcinoma. Cancer 83 1180-1188. (doi:10.1002/(SICI) 1097-0142(19980915) 83:6〈1180::AID-CNCR18〉3.0.CO;2-1)
82. Shahinian VB 2011 Androgen deprivation for prostate cancer: the case for "first, do no harm". Cancer [in press]. (doi:10.1002/cncr.26624)
83. Shaw JE, Sicree RA & Zimmet PZ 2010 Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87 4-14. (doi:10.1016/ j.diabres.2009.10.007)
84. Siegel R, Ward E, Brawley O & Jemal A 2011 Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians 61 212-236. (doi:10.3322/caac.20121)
85. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF & Davies JS 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. Journal of Clinical Endocrinology and Metabolism 86 4261-4267. (doi:10.1210/jc.86.9.4261)
86. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM & Shipley WU 2008 Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. Journal of Clinical Oncology 26 4333-4339. (doi:10.1200/JCO.2008.16.5845)
87. Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, Patel AV, Berndt SI, Albanes D & Hayes RB 2010 HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 70 601-607. (doi:10.1002/pros.21094)
88. Stewart SB & Freedland SJ 2011 Influence of obesity on the incidence and treatment of genitourinary malignancies. Urologic Oncology 29 476-486.
89. Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, Bensen JT & Mohler JL 2011 Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiology, Biomarkers & Prevention 20 844-853. (doi:10.1158/1055-9965.EPI-10-0684)
90. Svensson J, Kindblom J, Shao R, Moverare-Skrtic S, Lagerquist MK, Andersson N, Sjogren K, Venken K, Vanderschueren D, Jansson JO et al. 2008 Liver-derived IGF1 enhances the androgenic response in prostate. Journal of Endocrinology 199 489-497. (doi:10.1677/ JOE-08-0406)
91. Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, Ashida S, Miki T, Fujioka T, Shuin T et al. 2009 Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Research 69 8133-8140. (doi:10.1158/0008-5472.CAN-09-0775)
92. Tande AJ, Platz EA & Folsom AR 2006 The metabolic syndrome is associated with reduced risk of prostate cancer. American Journal of Epidemiology 164 1094-1102. (doi:10.1093/aje/kwj320)
93. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N & Lambe M 2011 Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 117 2086-2095. (doi:10.1002/cncr.25758)
94. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH & Pollak M 2007 Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. Journal of the National Cancer Institute 99 1793-1800. (doi:10.1093/jnci/djm231)
95. Vikan T, Schirmer H, Njolstad I & Svartberg J 2010 Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. European Journal of Endocrinology 162 747-754. (doi:10.1530/EJE-09-0943)
96. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN& Haiman CA 2009 Association of diabetes with prostate cancer risk in the multiethnic cohort. American Journal of Epidemiology 169 937-945. (doi:10.1093/aje/kwp003)
97. Waters KM, Wilkens LR, Monroe KR, Stram DO, Kolonel LN, Henderson BE, Le Marchand L & Haiman CA 2011 No association of type 2 diabetes risk variants and prostate cancer risk: the multiethnic cohort and PAGE. Cancer Epidemiology, Biomarkers & Prevention 20 1979-1981. (doi:10.1158/1055-9965.EPI- 11-0019)
98. Willemarck N, Rysman E, Brusselmans K, Van Imschoot G, Vanderhoydonc F, Moerloose K, Lerut E, Verhoeven G, van Roy F, Vleminckx K et al. 2010 Aberrant activation of fatty acid synthesis suppresses primary cilium formation and distorts tissue development. Cancer Research 70 9453-9462. (doi:10.1158/0008- 5472. CAN-10-2324)
99. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P & Morley JE 2003 Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 58 618-625. (doi:10.1093/gerona/58.7.M618)
100. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ & Brancati FL 2012 A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care 35 113-118. (doi:10.2337/ dc11-0255)
101. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G et al. 2008 Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature Genetics 40 638-645. (doi:10.1038/ng.120)